Tumorad-01 is progressing towards the DMC meeting and the study is about to expand the number of patients as well as the number of cancer types represented. The cost base is contained and the recent funding has increased the cash position to SEK 47.7m. Our updated base case is SEK 1.0 (1.0), Bull case SEK 2.6 (2.6) and a Bear Case of SEK 0.2 (0.2).